Cyborg | Designer-Babies | Futurism | Futurist | Immortality | Longevity | Nanotechnology | Post-Human | Singularity | Transhuman

Kolkata, Sep 2 (IANS) India's top public healthcare establishment, the All India Institute of Medical Sciences (AIIMS) in Delhi, is in talks with the Ohio State University (OSU) to set up the country's first comprehensive regenerative medicine centre that will open up avenues in research and development and introduce revolutionary techniques. Regenerative medicine, a broad subject, deals with …

Read more:
AIIMS, US varsity tie-up on India's first regenerative medicine centre

Senator Miriam Defensor Santiago has filed a bill seeking national strategy to support the research and development of regenerative medicine especially for treatment of diabetes, spinal cord injury, heart disease, stroke and various forms of cancer.

The senator recently announced that she had Stage Four lung cancer. She later said that the tumor had decreased in size.

Santiago, quoting the US Department of Health and Human Services, said the potential benefits of regenerative medicine in improved health care and economic savings were enormous.

Regenerative medicine products reportedly have been effective in the treatment of numerous diseases such as diabetes, spinal cord injury, heart disease, stroke, and various forms of cancer, she said.

She further said regenerative medicine represented the single most promising new approach to mitigating the human and economic costs of disease, and changing the course of human health.

Visit link:
Miriam files bill on govt funding for regenerative medicine

Scientists at the University of Edinburgh have grown a fully-functional organ inside a mouse; opening the possibility of one day manufacturing compatible organs for transplant without the need for donors. Using mouse embryo cells, scientists at the MRC Centre for Regenerative Medicine created an artificial thymus gland with the same structure and function as an adult organ.

Organ transplants are one of the great medical success stories of the 20th century. Where patients once faced disability or even death, they’ve been given new life in the form of donated organs to replace their damaged or diseased ones. The problem is that the supply of suitable donor organs has always been in a state of severe shortage. For decades, scientists have worked on producing lab-grown organs and even though such research has produced simple organs such as an artificial esophagus and “mini-kidneys,” the creation of whole, complex, functional organs has remained out of reach until now.

The University of Edinburgh team produced the artificial thymus gland using a technique that the scientists call “reprogramming.” It involves fibroblast cells, which form connective tissue in animals, being removed from a mouse embryo and then treated with a protein called FOXN1, so that they changed into thymic epithelial cells (iTEC). These were then mixed with other thymus cells and transplanted into living mice by grafting them to the animals kidneys.

There, over a period of four weeks, the cells grew into a complete, functioning thymus gland that can produce T cells, which are an important part of the immune system. According to the scientists, the development goes beyond previous efforts because the thymus serves such a key part in protecting the body against infection and in eliminating cancer cells.

The team is currently working on refining the reprogramming technique in the hope of developing a practical medical procedure, such as creating bespoke thymus glands made to match a patients own T cells. They see the development of a lab-grown thymus as a way of treating cancer patients whose immune system has been compromised by radiation or chemotherapy, and children born with malfunctioning thymuses.

“Growing ‘replacement parts’ for damaged tissue could remove the need to transplant whole organs from one person to another, which has many drawbacks not least a critical lack of donors,” says Rob Buckle, Head of Regenerative Medicine at the MRC. “This research is an exciting early step towards that goal, and a convincing demonstration of the potential power of direct reprogramming technology, by which one cell type is converted to another. However, much more work will be needed before this process can be reproduced in the lab environment, and in a safe and tightly controlled way suitable for use in humans.

The teams results were published in Nature Cell Biology.

The video below discusses the lab-grown thymus project.

Source: Centre for Regenerative Medicine

Read more:
Scientists grow fully-functioning organ inside a mouse from scratch

By Rebecca Smith in London

British scientists have built a complete and functional organ in a living animal for the first time.

The team produced it by reprogramming cells, in a step towards the holy grail of being able to grow replacement organs for humans.

The technique, so far tested only on mice, could be used in future to provide replacement organs for people with weakened immune systems, and could eventually lead to the production of more complex organs for transplantation.

It could be used in humans within 10 years, experts believe.

The scientists created a working thymus, a vital immune system nerve centre located near the heart.

Prof Clare Blackburn, who led the team at the Medical Research Council (MRC) Centre for Regenerative Medicine at the University of Edinburgh, said: The ability to grow replacement organs from cells in the lab is one of the holy grails in regenerative medicine. But the size and complexity of lab-grown organs has so far been limited.

By directly reprogramming cells, weve managed to produce an artificial cell type that, when transplanted, can form a fully organised and functional organ. This is an important first step towards the goal of generating a clinically useful artificial thymus in the lab.

People with a defective thymus are highly vulnerable to infections. This is a particular risk for bone-marrow-transplant patients, who need a working thymus to rebuild their immune systems after surgery.

Around one in 4,000 babies born each year in Britain has a malfunctioning thymus or none at all, because of rare conditions such as DiGeorge syndrome.

Read more:
Living organ grown in mice offers hope on transplants



GRECO MEDICAL GROUP : Regenerative Medicine
At Greco Medical Group (GMG) we use an advanced Regenerative (http://kneepainflorida.com/regenerative-medicine/) Medicine, utilize Platelet Rich Plasma (PRP) derived from the patient's own…

By: Jonathan Greco

Continue reading here:
GRECO MEDICAL GROUP : Regenerative Medicine – Video



Regenerative Medicine with PRP and Stem Cells at San Diego Center for Integrative Medicine
http://SDIntegrativeMedicine.com Regenerative medicine via platelet-rich plasma (PRP) and stem cells is more effective when used prior to surgery.

By: San Diego Center for Integrative Medicine

Go here to read the rest:
Regenerative Medicine with PRP and Stem Cells at San Diego Center for Integrative Medicine – Video



CGF – Concentrated Growth Factors with Medifuge
This is a short tutorial video about Concentrated Growth Factors or (CGF) using the Medifuge Centrifuge from Silfradent. Regenerative medicine is a key factor in rehabilitation dentistry today….

By: Implantknowhow

Link:
CGF – Concentrated Growth Factors with Medifuge – Video



Regenerative Medicine in Edinburgh
https://www.bhf.org.uk/get-involved/in-your-area/scotland/edinburgh-local-appeal.aspx Your donations power our amazing labs and the life-saving work that's g…

By: British Heart Foundation

Read more:
Regenerative Medicine in Edinburgh – Video

New York, California (PRWEB) August 28, 2014

The Manhattan Regenerative Medicine Medical Group announces a series of free public seminars on the use of adult stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief, and, Dr. Nia M. Smyrniotis, Medical Director.

The seminars will be held on Wednesday, September 3, 2014, at 2pm and 4pm at the City Limits Diner, at 135 Harvard Avenue, Stamford, CT 06902. Please RSVP at (917) 410-7391.

The Manhattan Regenerative Medicine Medical Group is an affiliate of the Miami Stem Cell Treatment Center, which abide by investigational protocols using adult adipose derived stem cells (ADSCs) which can be deployed to improve patients quality of life for a number of degenerative and chronic inflammatory conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (found within a cellular mixture called stromal vascular fraction (SVF). ADSCs are exceptionally abundant in adipose tissue. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly adult autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the body’s natural healing cells – they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys injured cells. The Manhattan Regenerative Medicine Medical Group and the Miami Stem Cell Treatment Center only use Adult Autologous Stem Cells from a person’s own fat No embryonic stem cells are used. Current areas of study include: Emphysema, COPD, Asthma, Heart Failure, Parkinsons Disease, Stroke, Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Crohns Disease, and degenerative orthopedic joint conditions. For more information, or if someone thinks they may be a candidate for one of the adult stem cell protocols offered by the Manhattan Regenerative Medicine Medical Group or Miami Stem Cell Treatment Center, they may contact Dr. Gionis or Dr. Nia directly at (917) 410-7391, or see a complete list of the Centers study areas at: http://www.MiamiStemCellsUSA.com or http://www.NYStemCellsUSA.com.

About Manhattan Regenerative Medicine Medical Group and the Miami Stem Cell Treatment Center: The Manhattan Regenerative Medicine Medical Group and The Miami Stem Cell Treatment Center is an affiliate of the Cell Surgical Network (CSN); they are located in Manhattan, NY; Miami, Boca Raton, and Orlando, Florida. We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Manhattan Regenerative Medicine Medical Group and the Miami Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Health, Office of Human Research Protection; and the study is registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information visit our website: http://www.MiamiStemCellsUSA.com or http://www.NYStemCellsUSA.com.

Read more here:
Adult Stem Cell Public Lecture New York Manhattan Regenerative Medicine Medical Group

RANCHO CORDOVA, Calif. — Cesca Therapeutics Inc. , an autologous cell-based regenerative medicine company, today announced the presentation to the Centers for Medicare and Medicaid Services ("CMS") …

Continue reading here:
Cesca Therapeutics Advocates Benefits of Cell Therapy to the Centers for Medicare and Medicaid Services

Boston, MA (PRWEB) August 29, 2014

A major challenge before new biotechnology start-up companies, especially ones in the biotech start-up dense realm of Boston-Cambridge, is gaining visibility that can lead to important strategic alliances and able investors. James Sherley, the Director of Bostons Adult Stem Cell Technology Center, LLC (ASCTC), has made increasing the local and national visibility of his company an important priority since he started the company in September 2013.

In addition to a social media marketing campaign launched earlier in July of this year, Director Sherley has targeted research and development conferences both nationally and internationally to increase industry awareness of ASCTCs unique portfolio of intellectual property available for licensing and its current commercial development targets. The company is focused on producing two products to address two important needs in drug development and regenerative medicine, respectively, that it is uniquely positioned to address.

ASCTCs most advanced product is an assay that can detect, very early in the drug development pipeline, drug candidates that will ultimately fail because of their toxicity to tissue stem cells. ASCTC developed the new technology in partnership with AlphaSTAR, Corporation, located in Long Beach, California. Currently, such lurking drugs are not detected until after expensive animal testing, more expensive clinical trials, or worse, after marketing. Director Sherley refers to the second product as, A future of pounds and pounds of normal adult tissue stem cells. The company holds a patented technology for mass production of human tissue stem cells. The initial production target is human liver stem cells that can be used to make mature human liver cells for use in drug development and to support liver transplant patients. The company also holds patents for production of pancreatic stem cells and hair follicle stem cells.

The sponsor the 2014 Stem Cells & Regenerative Medicine Conference, in Boston, September 15-16, Terrapinn, Inc., invited ASCTC to attend as a VIP guest. Although ASCTC will not make a formal presentation at this conference, Director Sherley will participate in a roundtable discussion on the topic, Articulating value for up-and-coming regenerative medicine, stem cell and cell-based therapies.

Later in September (22-24), Director Sherley will present one of the selected Next Generation Presentations for new companies at BioPharm America 2014, also taking place in Boston. In addition to the public presentation, ASCTC will also participate in confidential partnering meetings with potential investors and strategic alliance partners arranged by conference organizers.

In October, Director Sherley will present to a primarily academic research audience a more detailed accounting of ASCTCs computer simulation technology for quantifying tissue stem cells in culture. This technology is the basis for the companys new assay for tissue stem cell toxicity. Director Sherley is particularly interested in the response from several experts in tissue stem cell growth dynamics who are invited speakers. The symposium, which will take place at Rhode Island Hospital, a medical affiliate of Brown University in Providence, has the goal of presenting emerging disruptive research in the area of Novel Stem Cells and Vesicles. Director Sherley is a member of the symposium organizing committee. ************************************************************************************************************* The Adult Stem Cell Technology Center, LLC (ASCTC) is a Massachusetts life sciences company established in September 2013. ASCTC Director and founder, James L. Sherley, M.D., Ph.D. is the foremost authority on the unique properties of adult stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing iPSCs. Currently, ASCTC is employing its technological advantages to pursue commercialization of mass-produced therapeutic human liver cells and facile assays that are early warning systems for drug candidates with catastrophic toxicity due to adverse effects against adult tissue stem cells.

Read more here:
The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences …

BOTHELL, Wash., Aug. 25, 2014 /PRNewswire/ — BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today provided an update on adoption of the Company's proprietary HypoThermosol and CryoStor …

Read the original post:
BioLife Solutions CryoStor AND HypoThermosol Now Embedded In 130 Regenerative Medicine Clinical Trials



Hair Transplant Lecture in Brazil: Regenerative Medicine- PRP and ACell
Dallas hair transplant surgeon, Dr. Sam Lam, speaks at the 5th Brazilian Congress on Hair Restoration, held in Maresias, Brazil, on May 23, 2014, on the subj…

By: Samuel Lam

Go here to see the original:
Hair Transplant Lecture in Brazil: Regenerative Medicine- PRP and ACell – Video



Video Regenerative+Medicine+Workshop+promo+R4 HD
Annual Regenerative Medicine Workshop at Hilton Head, SC. The 2015 meeting will take place May 12-17 at the beautiful Sea Pines resort.

By: IBBGeorgiaTech

See original here:
Video Regenerative+Medicine+Workshop+promo+R4 HD – Video

Through regenerative medicine, your ADRCs can rebuild damaged muscle tissue

In the country, there is a facility identified as the first medical center in South East Asia to offer the most advanced regenerative medical procedures. It utilizes state-of-the-art processing, delivery, and preservation of medical-grade Adipose-Derived Regenerative Cells (ADRCs). Located at Zuellig Bldg. Makati Avenue cor. Paseo De Roxas, Makati City, EA Regenerative Medicine Center of Excellence follows the most stringent clinical protocols, registries and standards of operations.

The center makes use of the Celution System from Cytori Therapeutics USA. Their process involves the extraction of unwanted fats derived from the patients own body and isolating the healthy therapeutic cells which can then be administered for the treatment of a whole range of age-related conditions like cardiovascular diseases, orthopedics, muscle, ligament and soft tissue injuries, gastrointestinal disorders, pain management, and procedures for plastic and reconstructive surgery that ensure the safest, most natural, and efficient healing process available to modern health science.

SO HOW DOES IT WORK?

There are stem cells throughout the human body, but theyre rare and difficult to access. The problem facing companies interested in treatment models is this: in order to get therapeutic numbers, you have to grow the stem cells in cultures.

This process fundamentally transforms the cells, based on their time in culture. Under existing FDA regulations, it also effectively makes any treatment derived from a drug, with all the development costs, regulatory hurdles and expenses to get over before having a product to bring to patients.

Theres really not a tissue in the body where, with impunity and effectively no risk, you can take a liters worth from anybody, says David Oxley, Cytori vice president.

But there is your body fatthe thing most of us hate wearing around our waistlines the most.

Fat tissue is one of the sources of therapeutic levels of stem cells. Theres no comparison, says Dr. Eder Garcia Dizon, managing director of EA Regenerative Medicine Center of Excellence. Even bone marrow and cord blood as source pales in comparison from a volume and number of cells perspective.

The Celution system was devised by Cytori to get those cells from the patients fat tissue to their targeted area of need as quickly and efficiently as possible.

Read more from the original source:
Your fat can heal your heart



Neuroscience Daniel Medicine Kraft and Introduction to
Daniel Kraft, MD, speaking about Stem Cells Regenerative Medicine at Singularity University's Exponential Medicine Conference. FutureMed Executive Director and Singularity University Medicine…

By: carolina

Read more:
Neuroscience Daniel Medicine Kraft and Introduction to – Video

The Alliance for Regenerative Medicine , the international organization representing the interests of the advanced therapies and regenerative medicine community, supports the NIH decision announced today …

Originally posted here:
The Alliance for Regenerative Medicine Supports the NIH Decision to Change Role of Recombinant DNA Advisory Committee

La Mirada, CA (PRWEB) May 22, 2014

Healthpointe Medical Group is proud to announce that they are offering Regenerative Medicine Services at their facilities located throughout Southern California. Regenerative Medicine is a rapidly growing field that is aimed at restoring and/or replenishing the normal function of tissues that are damaged or otherwise affected by diseases. Through this program, Healthpointe provides simple, effective, and non-invasive Wound Care options to treat pain and various complex and non-healing wounds. This program is focused on providing patients with non-surgical approaches to treating a patients pain and providing state-of-the-art wound care. Healthpointes multidisciplinary team of physicians is ready to deliver quality wound care solutions to their patients. Their doctors adhere to the motto of delivering quality care to everyone, and they do so by offering customized treatment plans to better fit patients specific needs. Services under the Regenerative Medicine include:

Other Wound Care Services offered at Healthpointe:

These services may also be used in conjunction with surgical procedures to augment recovery time after surgery by enhancing the patients healing process. Regenerative Medicine services, along with the other Wound Care Services, are also known to decrease formation of scar tissues, especially after undergoing complex surgeries. Patients who are affected by soft tissue damage and difficult-to-heal wounds may finally find some resolution to their condition thanks to the new Regenerative Medicine services at Healthpointe. Healthpointes services are offered during regular business hours: Monday-Friday 9-6. For more information, contact Healthpointe at 844-887-7882 or visit the Healthpointe Website.

Go here to read the rest:
Regenerative Medicine Services Are Now Being Offered at Healthpointe

LONDON, United Kingdom — via PRWEB – Aging Analytics & The London Regenerative Medicine Network have co-published 'Investing in Regenerative Medicine: Technology Analysis & Market Outlook', a 106 page …

Read the original:
Live Long & Prosper? A New Report Highlights Economic & Health Benefits of A Growing Regenerative Medicine Sector

The Alliance for Regenerative Medicine and the American Society of Gene & Cell Therapy today announced their partnership. ARM's new Gene and Gene-Modified Cell Therapy Section brings together the leading …

Originally posted here:
Gene Therapy Section Formed Within the Alliance for Regenerative Medicine



FireFox! Start Your Own Web Hosting Company
Web Hosting Advertise Here $10 a Month Affordable web-hosting
Pierre Teilhard De Chardin




Designer Children | Prometheism | Euvolution | Transhumanism

Sign up below for the Prometheism / Designer Children Discussion Forum

Subscribe to prometheism-pgroup

Powered by us.groups.yahoo.com